BYD Atto 3 Challenges 'Too Hard' Viewpoint For BEVs

Feb. 28, 2023 12:30 PM ETBYD Company Limited (BYDDF), BYDDYBRK.A, BRK.B, TSLA7 Comments
Keith Williams profile picture
Keith Williams
8.33K Followers

Summary

  • After spending a lot of time and effort in building the international electric bus market, BYD is turning to passenger electric cars.
  • BYD is going global (except US) for cost-effective passenger fully-electric vehicles (BEVs). The BEV push includes Japan, which has resisted the switch from ICE to BEV.
  • There are two views of owning a BEV - one involves complexity, the other ease and big cost savings.
  • BYD’s new focus on global affordable personal transport BEVs is happening at a time of massive BEV adoption.
  • BYD has two negatives: Berkshire selling down and US distrust of everything Chinese; this may present an opportunity for investment in BYD.

Symbol for choosing a Hybrid Electric Vehicle (<a href='https://seekingalpha.com/symbol/HEV' _fcksavedurl='https://seekingalpha.com/symbol/HEV' title='Ener1 Inc'>HEV</a>) or a Battery Electric Vehicle (BEV)

Fokusiert/iStock via Getty Images

There's a lot to read about BEVs (Battery Electric Vehicles) currently and no doubt the upcoming Tesla (TSLA) March 1 Investor Day event will consume the headlines. One thing that has gone missing in a lot

This article was written by

Keith Williams profile picture
8.33K Followers
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science. Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity. Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering. With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.

Disclosure: I/we have a beneficial long position in the shares of TSLA, BYDDF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (7)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.